Labs in Court: A Full Circle
Cases filed or resolved by the U.S. Department of Justice in the fourth quarter reveal the same compliance issues from early in 2024
Author Information
Cases filed or resolved by the U.S. Department of Justice in the fourth quarter reveal the same compliance issues from early in 2024
Recent DOJ settlements continue to focus on issues involving medical necessity and marketer compensation
Examining DOJ and OIG investigations of labs and their owners: Recent cases show continued focus on the usual enforcement targets.
Recent enforcement actions show that clinical laboratories must remain vigilant about compliance relating to these areas
Recent cases show labs should be wary of issues such as improper relationships, medical necessity, kickbacks, and potential telehealth fraud.
The end of the COVID-19 public health emergency on May 11 also brings certain flexibilities for labs and other providers to an end.
As we move further into 2023, COVID-19, add-on, and genetic tests will likely remain targets for federal regulators.